Skip to main content
Fig. 2 | BMC Research Notes

Fig. 2

From: Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report

Fig. 2

Detection of BRAF V600E mutations in the patient’s plasma. Plasma was collected every day when the patient was in the hospital (9 days), and at each clinical evaluation (after 4 and 8 weeks of treatment). DNA was extracted from plasma (2 mL) using the QIAamp circulating nucleic acid kit (Qiagen). BRAF V600E mutations were detected and quantified by digital PCR using the QuantStudio 3D system and a specific BRAF V600E probe (Thermo Fischer, Courtaboeuf, France)

Back to article page